| 000 | 01718 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513054001.0 | ||
| 264 | 0 | _c19950117 | |
| 008 | 199501s 0 0 eng d | ||
| 022 | _a0142-2782 | ||
| 024 | 7 |
_a10.1002/bdd.2510150605 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYu, D K | |
| 245 | 0 | 0 |
_aA comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data. _h[electronic resource] |
| 260 |
_bBiopharmaceutics & drug disposition _cAug 1994 |
||
| 300 |
_a473-84 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_a4-Aminobutyrate Transaminase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnticonvulsants _xadministration & dosage |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCreatinine _xmetabolism |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Diseases _xblood |
| 650 | 0 | 4 | _aLikelihood Functions |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aModels, Statistical |
| 650 | 0 | 4 | _aTissue Distribution |
| 650 | 0 | 4 | _aVigabatrin |
| 650 | 0 | 4 |
_agamma-Aminobutyric Acid _xadministration & dosage |
| 700 | 1 | _aHutcheson, S J | |
| 700 | 1 | _aWei, G | |
| 700 | 1 | _aBhargava, V O | |
| 700 | 1 | _aWeir, S J | |
| 773 | 0 |
_tBiopharmaceutics & drug disposition _gvol. 15 _gno. 6 _gp. 473-84 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/bdd.2510150605 _zAvailable from publisher's website |
| 999 |
_c7993314 _d7993314 |
||